Chronic facial sarcoidosis including lupus pernio: Clinical description and proposed scoring systems

American Journal of Clinical Dermatology

Volumn 9, Issue 3, 2008, Pages 155-161

  Baughman, Robert P ^a,e   Judson, Marc A ^b   Teirstein, Alvin ^c   Lower, Elyse E ^a   Lo, Kim ^d   Schlenker Herceg, Rozsa ^d   Barnathan, Elliot S ^d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d CENTOCOR INC   (United States)

^e NONE   (United States)

Author keywords

Diagnostics; Sarcoidosis, diagnosis

Indexed keywords

AZATHIOPRINE; DOXYCYCLINE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; PREDNISONE; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTROLLED STUDY; DESQUAMATION; ERYTHEMA; EYE DISEASE; FACE DISORDER; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SARCOIDOSIS; SARCOIDOSIS ACTIVITY AND SEVERITY INDEX; SCORING SYSTEM; SKIN INDURATION; SYMPTOMATOLOGY;

ADULT; CHRONIC DISEASE; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX;

EID: 42449162247     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809030-00003     Document Type: Article

References (34)

1. James DG. Lupus pernio. Lupus 1992 May; 1 (3): 129-31
2. Spiteri MA, Matthey F, Gordon T, et al. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 1985 Mar; 112 (3): 315-22
3. Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995 May; 131 (5): 617-8
4. Chloroquine in the treatment of sarcoidosis: a report from the Research Committee of the British Tuberculosis Association. Tubercle 1967 Dec; 48 (4): 257-72
5. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 1964; 425: 302S-8S
6. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-51
7. Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24: 451-4
8. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-8
9. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122: 227-32
10. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32 (5 Pt 2): 866-9
11. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998 Nov; 39 (5 Pt 2): 835-8
12. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004 Feb; 50 (2): 235-41
13. Oliver SJ, Kikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002 Mar; 102 (3): 225-36
14. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4
15. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005 Mar; 127 (3): 1064-71
16. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004 Jan; 150 (1): 146-9
17. Roberts SD, Wilkes DS, Burgett RA, et al. Refractory sarcoidosis responding to infliximab. Chest 2003 Nov; 124 (5): 2028-31
18. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999 Sep; 16 (2): 149-73
19. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86
20. Altaye M, Donner A, Eliasziw M. A general goodness-of-fit approach for inference procedures concerning the kappa statistic. Stat Med 2001 Aug 30; 20 (16): 2479-88
21. Neville E, Mills RG, Jash DK, et al. Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax 1976 Dec; 31 (6): 660-4
22. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990 Sep; 23 (3 Pt 1): 487-9
23. Zic J, Horowitz D, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature. Arch Dermatol 1991; 127: 1034-40
24. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001 Jan; 137 (1): 69-73
25. Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003 Feb; 48 (2): 290-3
26. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005 Mar; 64 Suppl. 2: ii65-8; discussion ii69-73
27. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210 (3): 194-9
28. Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996 Jan; 106 (1): 183-6
29. Marchell RM, Judson MA. Chronic cutaneous lesions of sarcoidosis. Clin Dermatol 2007 May; 25 (3): 295-302
30. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004 Oct; 51 (4): 563-9
31. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005 Apr; 52 (4): 1227-36
32. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004 Jun; 50 (6): 859-66
33. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 Dec 17; 290 (23): 3073-80
34. Fernandez C, Adamson K, Dale M, et al. A randomized double-blind study to assess the effects of silicic acid compared to placebo in patients with mild to moderate acne. J Dermatolog Treat 2005; 16 (5-6): 287-94